Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib + Nab-Paclitaxel in mPDAC
NCT02501902Phase 1Completed
- Sponsor
- Pfizer
- Start
- Nov 2015
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of palbociclib in pancreatic ductal adenocarcinoma (PDAC), sponsored by Pfizer. Primary endpoint: Number of Participants With Dose Limiting Toxicities. Started Nov 2015; status: completed.
02
Drugs
palbociclib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02501902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02501902.